Published Date: 16 Feb 2023
Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.
Read Full NewsClosing the COVID-19 Prevention Gap This Flu Season, With Juanita Mora, MD
Darren Gitelman, MD, senior medical director of the Advocate Memory Center in Park Ridge, discusses findings linking high-dose influenza vaccination to lower Alzheimer disease risk, study limitations, and potential implications for future dementia prevention research.
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
1.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
2.
High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.
3.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
4.
Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.
5.
FDA Approves Subcutaneous Isatuximab for MM Indications
1.
Strategic Deals and FDA Approvals Transforming U.S. Oncology Drug Development
2.
Beyond the Biopsy: Decoding Tumor Biology Through the Lens of Radiogenomics
3.
The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts
4.
Molecular Mechanisms of Chromatin Condensation During Persistent Cellular Stress
5.
Clonal Evolution Genomics in Dynamic Tumor Ecosystems
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
3.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
4.
Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance
5.
Updates on the First Line Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation